Analogous to IFN-β-Treated MS Patients, Patients with Depression, Systemic Lupus Erythematosus or Parkinson’s Disease are Characterized by Increased Plasma Ceramides. This evidence concerns the gene IFNB1 and myeloid sarcoma.